Want $1 Million in Retirement? Invest $10,000 in These 2 AI Stocks and Hold for 10 Years.

Tempus AI has $1.27 billion in trailing revenue driven by a clinical-data flywheel that the article argues competitors cannot build from scratch, implying a durable competitive moat. Recursion is using AI to generate drug candidates much more efficiently than the overall industry, suggesting potential faster R&D productivity and differentiation for AI-first biotech players.

Analysis

Tempus AI has $1.27 billion in trailing revenue driven by a clinical-data flywheel that the article argues competitors cannot build from scratch, implying a durable competitive moat. Recursion is using AI to generate drug candidates much more efficiently than the overall industry, suggesting potential faster R&D productivity and differentiation for AI-first biotech players.